Study design
AD dementia
This was a phase II, 12-week, multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group comparison in patients with mild-to-moderate probable AD dementia between August 18, 2016, and October 11, 2019 (NCT02788513; EudraCT Number: 2015-005438-24; Fig. Study design. R, randomized; S, screened populationThe trial was carried out in compliance with the approved clinical trial protocol, which was in accordance with the principles of the Declaration of Helsinki [